Eris Lifesciences Disrupts the GLP-1 Market with ₹220 Semaglutide Shot

Eris Lifesciences Disrupts the GLP-1 Market with ₹220 Semaglutide Shot

By, Admin 23 March 2026

The semaglutide price war in India just hit a new low. Eris Lifesciences Limited has launched its generic semaglutide under the brand SUNDAE, starting at just ₹220 per weekly shot.

This is not a small move. It’s a direct attempt to democratize access to GLP-1 therapies in one of the world’s largest diabetes markets.

The Offer: Ultra-Low-Cost Weekly Therapy

Eris is launching SUNDAE in multi-dose vial formats first.

Pricing breakdown:

  • Starting at ₹1,290 per month
  • Available strengths:
    • 2 mg / 1.5 mL
    • 4 mg / 3 mL

This makes it one of the most affordable semaglutide options globally

What’s Coming Next: Pen Devices?

Eris isn’t stopping at vials. A pen-device version is launching in April with pricing:

  • ₹4,000/month (2 mg)
  • ₹4,200/month (4 mg)
  • ₹4,500/month (8 mg)

Why this matters:

  • Vials → affordability
  • Pens → convenience

A dual strategy to capture both price-sensitive and premium users

The Big Claim: 70% Patient Reach

Eris estimates this pricing could make GLP-1 therapy accessible to: ~70% of India’s diabetes population That’s massive—especially in a country where affordability is the biggest barrier.

Why Semaglutide Is Driving This Race?

Semaglutide (a GLP-1 receptor agonist) has become a blockbuster class because it:

  • Improves glycaemic control
  • Drives significant weight loss
  • Reduces cardiovascular risks

It’s now seen as a next-generation therapy for:

  • Type 2 diabetes
  • Obesity
  • Broader metabolic disorders

The Strategy: Volume Over Margin

Eris is clearly not playing the premium game.

Instead, it’s betting on:

  • Aggressive pricing
  • Rapid adoption
  • High patient volume

This is a classic India-first market capture strategy.

Where Eris Fits in the Competitive Landscape

Let’s put this into context:

Sun Pharmaceutical Industries Limited

  • ₹750–₹2,000/week range
  • Strong brand + device ecosystem

Dr. Reddy’s Laboratories Ltd.

  • ~₹4,200/month
  • First-mover in generics
  • Strong clinical backing

Eris Lifesciences

  • ₹220/week (lowest entry point)
  • Vial-first strategy
  • Expanding to pens

Eris is clearly targeting the mass market segment

The Real Play: Diabetology Dominance

Eris already has:

  • Strong relationships with diabetologists
  • Deep presence in chronic care
  • A diversified specialty portfolio

Adding semaglutide:

  • Strengthens its diabetes franchise
  • Positions it in next-gen metabolic therapies
  • Increases share of prescription in high-growth segment

The Bigger Trend: GLP-1 Market Fragmentation in India

India is becoming a multi-tier semaglutide market:

Tier 1: Ultra-affordable

  • Eris (vials)

Tier 2: Mid-range

  • Sun Pharma
  • Other branded generics

Tier 3: Premium / global innovators

  • Higher-dose, high-efficacy products

This segmentation will define market share over the next 3–5 years

The Bottom Line

Eris is not trying to out-innovate competitors. It’s trying to out-distribute and out-price them.

  • Lowest entry cost in the market
  • Massive potential patient reach
  • Strong diabetology network

If execution matches ambition: SUNDAE could become the fastest-scaling GLP-1 brand in India

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!